Bumetanide vs Bimatoprost: side-by-side comparison
Bumetanide (Loop diuretic) and Bimatoprost (Prostaglandin analogue) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Bumetanide | Bimatoprost |
|---|---|---|
| Therapeutic class | Loop diuretic | Prostaglandin analogue |
| CAS | 28395-03-1 | 155206-00-1 |
| ATC | C03CA02 | S01EE03 |
| Molecular weight | 364.42 g/mol | 415.57 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Bumetanide and Bimatoprost share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Bumetanide acts by a different mechanism than Bimatoprost, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Bumetanide: Bumetanide blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, producing potent natriuresis and diuresis. Bimatoprost: Bimatoprost is a prostamide analogue that increases aqueous humour outflow through both the trabecular meshwork and the uveoscleral pathway, lowering intraocular pressure.
Indications compared
Bumetanide: Bumetanide is approved for oedema in heart failure, hepatic cirrhosis or chronic kidney disease, and for refractory oedema unresponsive to other diuretics. Bimatoprost: Bimatoprost is approved in adults for the treatment of ocular hypertension and chronic open-angle glaucoma.
Safety profile
Bumetanide: Common adverse effects include hypokalaemia, hyponatraemia, hypomagnesaemia, dehydration, hyperuricaemia, hyperglycaemia, ototoxicity (rare, dose-dependent) and orthostatic hypotension. Bimatoprost: Common adverse effects include conjunctival hyperaemia, ocular irritation, eyelash growth and darkening, and progressive iris pigmentation, which is permanent.
Frequently asked questions
Is Bumetanide better than Bimatoprost? ▾
Bumetanide and Bimatoprost are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Bumetanide and Bimatoprost be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Bumetanide
Products with Bimatoprost
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.